Icon Bioscience Inc. has kept development of its pipeline of drugs targeting ophthalmic indications largely under wraps. That posture may change as lead candidate IBI-10090, designed to treat inflammation associated with cataract surgery, moves through a pivotal phase III trial that completed enrollment four months ahead of schedule.